Основная статистика
| CIK | 1863294 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to DA32 Life Science Tech Acquisition Corp - Class A
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 7, 2024 |
SC 13G/A 1 formsc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* DA32 Life Science Tech Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 23312M106 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Stat |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DA32 Life Science Tech Acquisition Corp (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 23312M106 (CUSIP Number) August 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-40676 DA32 LIFE SCIENCE TECH ACQUISITION CORP. (Exact name of registran |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) Mark McDonnell ARCH Venture Management, LLC 8755 W. Higgins Road Suite 1025 Chicago, IL 60631 (Name, Ad |
|
| August 2, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) Steve Kafka DA32 Life Science Tech Acquisition Corp. 345 Park Avenue, 12th Floor New York, NY 10010 (212) 551- |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) David Clark Deerfield Management Company, L.P. 345 Park Avenue, 12th Floor New York, NY 10010 (212) 551-1600 Copy to: J |
|
| August 1, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) Steve Kafka DA32 Life Science Tech Acquisition Corp. 345 Park Avenue, 12th Floor New York, NY 10010 (212) 551- |
|
| July 21, 2023 |
DA32 Life Science Tech Acquisition Corp. Announces Redemption of Shares EX-99.1 Exhibit 99.1 DA32 Life Science Tech Acquisition Corp. Announces Redemption of Shares NEW YORK, July 21, 2023 — DA32 Life Science Tech Acquisition Corp. (Nasdaq: DALS) today announced that its board of directors (the “Board”) has determined to redeem all of its outstanding shares of Class A common stock (the “Public Shares”), effective as of July 28, 2023, because the Company will not consu |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2023 DA32 Life Science Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 001-40676 86-3352988 (State or other jurisdiction of incorporati |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 23312M106 (CUSIP Number) May 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| May 12, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40676 DA |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DA32 Life Science Tech Acquisition Corp (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 23312M106 (CUSIP Number) March 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate |
|
| March 29, 2023 |
Consulting Agreement, dated January 13, 2023, by and between the Company and Amanda Murphy. EX-10.8 Exhibit 10.8 EXECUTION VERSION CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”), dated as of January 13, 2023 (the “Effective Date”), is entered into by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the “Company”), and Amanda Murphy (“Consultant”) (collectively referred to as the “Parties” or individually referred to as a “Party”) WHEREAS, C |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-40676 DA32 LIFE SCIENCE TECH ACQ |
|
| February 14, 2023 |
SC 13G/A 1 formsc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* DA32 Life Science Tech Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 23312M106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Stat |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No.1 )* DA32 Life Science Tech (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| November 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-4067 |
|
| August 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40676 DA3 |
|
| May 13, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40676 DA |
|
| March 31, 2022 |
Exhibit 10.9 DA32 LIFE SCIENCE TECH ACQUISITION CORP. 345 Park Avenue South, 12th Floor New York, NY 10010 July 27, 2021 Deerfield Partners, L.P. 345 Park Avenue South, 12th Floor New York, NY 10010 Re: Amended and Restated Administrative Services Agreement Ladies and Gentlemen: This letter agreement (this ?Agreement?) by and between DA32 Life Science Tech Acquisition Corp. (the ?Company?) and Dee |
|
| March 31, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-40676 DA32 LIF |
|
| March 31, 2022 |
Exhibit 4.2 Description of shares We are a Delaware corporation and our affairs are governed by our amended and restated certificate of incorporation and the DGCL. Pursuant to our amended and restated certificate of incorporation, which was adopted prior to the consummation of our initial public offering on July 30, 2021 (the ?Public Offering?), we are authorized to issue 110,000,000 shares of com |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) January 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DA32 Life Science Tech Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 23312M106 (CUSIP Number) January 28, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 2, 2022 |
SC 13G 1 da32lifescience13g123121.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* DA32 Life Science Tech (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 15, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-4067 |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| August 10, 2021 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) Steve Kafka DA32 Life Science Tech Acquisition Corp. 345 Park Avenue, 12th Floor New York, NY 10010 (212) 551-1600 Copy to: Joel L |
|
| August 10, 2021 |
Joint Filing Agreement by and among the Reporting Persons. EX-11 3 d120533dex11.htm EX-11 Exhibit 11 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (in |
|
| August 10, 2021 |
Exhibit 1 Agreement This letter agreement, dated July 26, 2021, is made by and among Deerfield Partners, L. |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) David Clark Deerfield Management Company, L.P. 345 Park Avenue, 12th Floor New York, NY 10010 (212) 551-1600 Copy to: Joel L. Rubinstein |
|
| August 10, 2021 |
Joint Filing Agreement by and among the Reporting Persons. Exhibit 11 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the ?Exchange Act?) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities of DA32 Life Science Tech Acquisition Corp. |
|
| August 10, 2021 |
Joint Filing Agreement by and among the Reporting Persons. EX-11 3 d146494dex11.htm EX-11 Exhibit 11 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (in |
|
| August 10, 2021 |
Exhibit 1 Agreement This letter agreement, dated July 26, 2021, is made by and among Deerfield Partners, L. |
|
| August 10, 2021 |
Exhibit 1 Agreement This letter agreement, dated July 26, 2021, is made by and among Deerfield Partners, L. |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) Steve Kafka DA32 Life Science Tech Acquisition Corp. 345 Park Avenue, 12th Floor New York, NY 10010 (212) 551-1600 Copy to: Joel L. Rubin |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 23312M 106 (CUSIP Number) Steve Kafka DA32 Life Science Tech Acquisition Corp. 345 Park Avenue, 12th Floor New York, NY 10010 (212) 551-1600 Copy to: Joel L. Rubin |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 23312M106 (CUSIP Number) July 28, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DA32 Life Science Tech Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 23312M106 (CUSIP Number) July 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| August 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2021 DA32 LIFE SCIENCE TECH ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-40676 86-3352988 (State or other jurisdiction of incorporati |
|
| August 5, 2021 |
Exhibit 99.1 DA32 LIFE SCIENCE TECH ACQUISITION CORP. Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of DA32 Life Science Tech Acquisition Corp. Opinion on the Financial Statement We have audited the accompanying balance sheet of DA3 |
|
| July 30, 2021 |
Exhibit 10.6 STRATEGIC SERVICES AGREEMENT This Agreement is made on this 27th day of July, 2021 by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), and Christopher Wolfe (the ?Strategic Consultant?). The Company and Strategic Consultant are sometimes hereinafter referred to singly as the ?Party? and, collectively, as the ?Parties.? WHEREAS, the Strategi |
|
| July 30, 2021 |
Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this ?Agreement?) is made effective as of July 27, 2021 by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the ?Trustee?). WHEREAS, the Company?s registration statement |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2021 (July 27, 2021) DA32 LIFE SCIENCE TECH ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-40676 86-3352988 (State or other jurisdictio |
|
| July 30, 2021 |
Exhibit 10.1 July 27, 2021 DA32 Life Science Tech Acquisition Corp. 345 Park Avenue South, 12th Floor New York, NY 10010 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and among DA32 Life Science Tech Acquisition Corp., a Delaware corporati |
|
| July 30, 2021 |
Exhibit 10.5 DA32 LIFE SCIENCE TECH ACQUISITION CORP. 345 Park Avenue South, 12th Floor New York, NY 10010 July 27, 2021 DA32 Sponsor LLC 345 Park Avenue South, 12th Floor New York, NY 10010 Re: Administrative Services Agreement Ladies and Gentlemen: This letter agreement (this ?Agreement?) by and between DA32 Life Science Tech Acquisition Corp. (the ?Company?) and DA32 Sponsor LLC (the ?Sponsor?) |
|
| July 30, 2021 |
Amended and Restated Certificate of Incorporation. EX-3.1 3 d198820dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DA32 LIFE SCIENCE TECH ACQUISITION CORP. July 27, 2021 DA32 Life Science Tech Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “DA32 Life Science Tech Acquisition Corp. |
|
| July 30, 2021 |
Exhibit 99.2 DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, ARCH Venture Partners and Section 32, Announces Closing of $200 Million Initial Public Offering NEW YORK, July 30, 2021 ? DA32 Life Science Tech Acquisition Corp. (the ?Company?) announced today the closing of its initial public offering of 20,000,000 shares of Class A common stock at a price of $10.00 per share. The Cl |
|
| July 30, 2021 |
Exhibit 99.1 DA32 Life Science Tech Acquisition Corp., Sponsored by Deerfield, Arch Venture Partners and Section 32, Announces Pricing of $200 Million Initial Public Offering NEW YORK, July 27, 2021 ? DA32 Life Science Tech Acquisition Corp. (the ?Company?) announced today the pricing of its initial public offering of 20,000,000 shares of Class A common stock at a price of $10.00 per share. The Cl |
|
| July 30, 2021 |
Exhibit 10.4 PRIVATE PLACEMENT CLASS A COMMON STOCK PURCHASE AGREEMENT THIS PRIVATE PLACEMENT CLASS A COMMON STOCK PURCHASE AGREEMENT, dated as of July 27, 2021 (as it may from time to time be amended, this ?Agreement?), is entered into by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), and DA32 Sponsor LLC, a Delaware limited liability company (the ?P |
|
| July 30, 2021 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of July 27, 2021, is made and entered into by and among DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), DA32 Sponsor LLC, a Delaware limited liability company (the ?Sponsor?) and the undersigned parties listed on the signature page hereto under ?Holders? (eac |
|
| July 30, 2021 |
Exhibit 1.1 DA32 LIFE SCIENCE TECH ACQUISITION CORP. 20,000,000 Shares of Class A Common Stock UNDERWRITING AGREEMENT July 27, 2021 J.P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 1 |
|
| July 29, 2021 |
The accompanying notes are an integral part of these financial statements. Table of Contents Filed Pursuant to 424(b)(4) Registration No. 333-257679 Prospectus $200,000,000 DA32 Life Science Tech Acquisition Corp. 20,000,000 Shares of Class A common stock DA32 Life Science Tech Acquisition Corp. is a blank check company formed as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or simi |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 DA32 Life Science Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware` 86-3352988 (State of incorporation or organization) (I.R.S. Employer Identification No.) |
|
| July 23, 2021 |
DA32 Life Science Tech Acquisition Corp. 345 Park Avenue South, 12th Floor New York, NY 10010 DA32 Life Science Tech Acquisition Corp. 345 Park Avenue South, 12th Floor New York, NY 10010 July 23, 2021 VIA EDGAR Folake K. Ayoola U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: DA32 Life Science Tech Acquisition Corp. Registration Statement on Form S-1 Filed July 2, 2021, as amended File No. 333-257679 Dear Ms. Ayoola: Pur |
|
| July 23, 2021 |
J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 July 23, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: DA32 Life Science Tech Acquisition Corp. Registration Statement on Form S-1 Filed July 2, 2021, as amended Fi |
|
| July 15, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 15, 2021. Table of Contents As filed with the U.S. Securities and Exchange Commission on July 15, 2021. Registration No. 333-257679 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DA32 Life Science Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 86-3352988 ( |
|
| July 15, 2021 |
CORRESP 1 filename1.htm July 15, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance Office of Real Estate & Construction 100 F Street, NE Washington, D.C. 20549 Attn: Jan Woo Folake Ayoola Re: DA32 Life Science Tech Acquisition Corp. Registration Statement on Form S-1 Filed July 2, 2021 File No. 333-257679 Ladies and Gentlemen: On behalf of our client, DA |
|
| July 2, 2021 |
Form of Administrative Services Agreement between the Registrant and DA32 Sponsor LLC.* Exhibit 10.8 DA32 LIFE SCIENCE TECH ACQUISITION CORP. 345 Park Avenue South, 12th Floor New York, NY 10010 [?], 2021 DA32 Sponsor LLC 345 Park Avenue South, 12th Floor New York, NY 10010 Re: Administrative Services Agreement Ladies and Gentlemen: This letter agreement (this ?Agreement?) by and between DA32 Life Science Tech Acquisition Corp. (the ?Company?) and DA32 Sponsor LLC (the ?Sponsor?), da |
|
| July 2, 2021 |
Exhibit 10.2 FORM OF INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this ?Agreement?) is made effective as of [?], 2021 by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the ?Trustee?). WHEREAS, the Company?s registration statem |
|
| July 2, 2021 |
Form of Strategic Services Agreement between the Registrant and Christopher Wolfe.* Exhibit 10.9 STRATEGIC SERVICES AGREEMENT This Agreement is made on this [?] day of [?], 2021 by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), and Christopher Wolfe (the ?Strategic Consultant?). The Company and Strategic Consultant are sometimes hereinafter referred to singly as the ?Party? and, collectively, as the ?Parties.? WHEREAS, the Strategic |
|
| July 2, 2021 |
Consent of Andrew ElBardissi.* Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the ?Company?) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee to the |
|
| July 2, 2021 |
Exhibit 99.8 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the ?Company?) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee to the |
|
| July 2, 2021 |
Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of [ ], 2021, is made and entered into by and among DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), DA32 Sponsor LLC, a Delaware limited liability company (the ?Sponsor?) and the undersigned parties listed on the signature page hereto under ?Holders? |
|
| July 2, 2021 |
EX-3.1 3 d184855dex31.htm EX-3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF DA32 LIFE SCIENCE TECH ACQUISITION CORP. April 16, 2021 The undersigned, for the purposes of forming a corporation under the laws of the State of Delaware, does make, file, and record this Certificate of Incorporation (the “Certificate”), and does hereby certify as follows: ARTICLE I NAME The name of the corporation is DA |
|
| July 2, 2021 |
Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the ?Company?) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee to the |
|
| July 2, 2021 |
Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the ?Company?) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee to the |
|
| July 2, 2021 |
Specimen Class A Common Stock Certificate.* Exhibit 4.1 NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [?] DA32 LIFE SCIENCE TECH ACQUISITION CORP. CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of fully paid and non-assessable shares of Class A common stock, par value $0.0001 per share (the ?Common Stock?), of DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), transferable on the books of t |
|
| July 2, 2021 |
Form of Amended and Restated Certificate of Incorporation.* Exhibit 3.2 FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DA32 LIFE SCIENCE ACQUISITION CORP. [ ], 2021 DA32 Life Science Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is ?DA32 Life Science Acquisition Corp.?. The original certificate of incorporation |
|
| July 2, 2021 |
Exhibit 10.4 FORM OF PRIVATE PLACEMENT CLASS A COMMON STOCK PURCHASE AGREEMENT THIS PRIVATE PLACEMENT CLASS A COMMON STOCK PURCHASE AGREEMENT, dated as of [?], 2021 (as it may from time to time be amended, this ?Agreement?), is entered into by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), and DA32 Sponsor LLC, a Delaware limited liability company (th |
|
| July 2, 2021 |
Exhibit 10.1 [?], 2021 DA32 Life Science Tech Acquisition Corp. 345 Park Avenue South, 12th Floor New York, NY 10010 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and among DA32 Life Science Tech Acquisition Corp., a Delaware corporation ( |
|
| July 2, 2021 |
Power of Attorney (included on signature page of Form S-1).* Table of Contents As filed with the U.S. Securities and Exchange Commission on July 2, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DA32 Life Science Tech Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 6770 86-3352988 (State or other jurisdictio |
|
| July 2, 2021 |
Form of Audit Committee Charter.* Exhibit 99.1 DA32 LIFE SCIENCE TECH ACQUISITION CORP. FORM OF AUDIT COMMITTEE CHARTER Effective [ ], 2021 I. PURPOSES The Audit Committee (the ?Committee?) is appointed by the Board of Directors (the ?Board?) of DA32 Life Science Tech Acquisition Corp. (the ?Company?) to assist the Board in its oversight of the accounting and financial reporting processes of the Company and the Company?s complianc |
|
| July 2, 2021 |
Form of Underwriting Agreement.* Exhibit 1.1 DA32 LIFE SCIENCE TECH ACQUISITION CORP. 20,000,000 Shares of Class A Common Stock UNDERWRITING AGREEMENT [ ], 2021 J.P. Morgan Securities LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 |
|
| July 2, 2021 |
Exhibit 10.7 DA32 Life Science Tech Acquisition Corp. May 13, 2021 DA32 Sponsor LLC RE: Securities Subscription Agreement Ladies and Gentlemen: This agreement (the ?Agreement?) is entered into on May 13, 2021 by and between DA32 Sponsor LLC, a Delaware limited liability company (the ?Subscriber? or ?you?), and DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?, ?we? or |
|
| July 2, 2021 |
CORRESP 1 filename1.htm July 2, 2021 VIA EDGAR United States Securities and Exchange Commission White & Case LLP 1221 Avenue of the Americas New York, NY 10020-1095 T +1 212 819 8200 whitecase.com Division of Corporate Finance Office of Real Estate & Construction 100 F Street, NE Washington, D.C. 20549 Attn: Jan Woo Folake Ayoola Re: DA32 Life Science Tech Acquisition Corp. Draft Registration Stat |
|
| July 2, 2021 |
Exhibit 14 DA32 LIFE SCIENCE TECH ACQUISITION CORP. FORM OF CODE OF ETHICS Effective [ ], 2021 I. INTRODUCTION The Board of Directors (the ?Board?) of DA32 Life Science Tech Acquisition Corp. has adopted this code of ethics (this ?Code?), as amended from time to time by the Board and which is applicable to all of the Company?s directors, officers and employees (to the extent that employees are hir |
|
| July 2, 2021 |
Exhibit 3.3 BY LAWS OF DA32 LIFE SCIENCE TECH ACQUISITION CORP. (THE ?CORPORATION?) ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corporation?s registered |
|
| July 2, 2021 |
Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the ?Company?) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee to the |
|
| July 2, 2021 |
Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the ?Company?) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee to the |
|
| July 2, 2021 |
Form of Compensation Committee Charter.* Exhibit 99.2 DA32 LIFE SCIENCE TECH ACQUISITION CORP. FORM OF COMPENSATION COMMITTEE CHARTER Effective [ ], 2021 I. PURPOSES The Compensation Committee (the ?Committee?) is appointed by the Board of Directors (the ?Board?) of DA32 Life Science Tech Acquisition Corp. (the ?Company?) to: (A) assist the Board in overseeing the Company?s employee compensation policies and practices, including (i) dete |
|
| July 2, 2021 |
Promissory Note issued to DA32 Sponsor LLC. Exhibit 10.6 THIS PROMISSORY NOTE (?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY |
|
| July 2, 2021 |
Exhibit 10.5 FORM OF INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) is made as of , 2021, by and between DA32 Life Science Tech Acquisition Corp., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided |
|
| May 28, 2021 |
Consent to be Named as a Director Nominee EX-99.4 3 filename3.htm Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the “Company”) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 under the Securities Act, to being na |
|
| May 28, 2021 |
DRS 1 filename1.htm Table of Contents As confidentially submitted to the U.S. Securities and Exchange Commission on May 28, 2021. This draft registration statement has not been filed, publicly or otherwise, with the U.S. Securities and Exchange Commission and all information contained herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washi |
|
| May 28, 2021 |
Consent to be Named as a Director Nominee EX-99.3 Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by DA32 Life Science Tech Acquisition Corp. (the “Company”) of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 under the Securities Act, to being named as a nominee |
